Exclusive: Briggs Morrison's Crossbow Therapeutics nabs $80M from MPM, Pfizer Ventures, Lilly in hunt for better cancer drugs
Briggs Morrison is ready to take on cancer with a new arsenal of antibodies that his biotech hopes will be more precise and tumor-killing than previous immunotherapies.
Crossbow Therapeutics has reeled in an $80 million Series A led by founder MPM BioImpact alongside Pfizer Ventures, with funds also coming from Eli Lilly, Polaris Partners, BVF Partners and Mirae.
MPM’s Patrick Baeuerle, Todd Foley and Geraldine Paulus founded the Cambridge, MA-based biotech to make new therapies that go after the peptide-loaded major histocompatibility complexes, or pMHCs, on cancer cells. They’re specifically going after intracellular cancer targets, even secreted proteins, which Crossbow hopes will broaden the reach of antibodies, said Morrison, the CEO.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.